title: European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization.
abstract: BACKGROUND
  Plerixafor with granulocyte-colony-stimulating factor (G-CSF) has been shown to enhance stem cell mobilization in patients with multiple myeloma and lymphoma with previous mobilization failure. In this European named patient program we report the experience in insufficiently mobilizing patients diagnosed with nonhematologic diseases.
  
  
  METHODS
  Thirty-three patients with germ cell tumor (n=11), Ewing sarcoma (n=6), Wiscott-Aldrich disease (n=5), neuroblastoma (n=4), and other nonhematologic diseases (n=7) were included in the study. Plerixafor was limited to patients with previous or current stem cell mobilization failure and given after 4 days of G-CSF (n=21) or after chemotherapy and G-CSF (n=12) in patients who mobilized poorly.
  
  
  RESULTS
  Overall, 28 (85%) patients succeeded in collecting at least 2×10(6)/kg body weight (b.w.) CD34+ cells (median, 5.0×10(6)/kg b.w. CD34+ cells; range, 2.0×10(6)-29.5×10(6)/kg b.w. CD34+ cells), and five (15%) patients collected a median of 1.5×10(6)/kg b.w. CD34+ cells (range, 0.9×10(6)-1.8×10(6)/kg b.w. CD34+ cells). Nineteen patients proceeded to transplantation. The median dose of CD34+ cells infused was 3.3×10(6)/kg b.w. (range, 2.3×10(6)-6.7×10(6)/kg b.w. CD34+ cells). The median numbers of days to neutrophil and platelet engraftment were 11 (range, 9-12) and 15 (range, 10-25) days, respectively.
  
  
  CONCLUSIONS
  These data emphasize the role of plerixafor in combination with G-CSF or chemotherapy and G-CSF as an effective mobilization regimen with the potential of successful stem cell collection. Accordingly, plerixafor seems to be safe and effective in patients with nonhematologic diseases. Larger prospective studies are warranted to further assess its use in these patients.
authors.affiliation: Department of Bloodgroup Serology and Transfusion Medicine, Medical University of Vienna, Viena, Austria. nina.worel@meduniwien.ac.at
authors.forename: Nina
authors.initials: N
authors.lastname: Worel
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
authors.forename: Grzegorz W
authors.initials: GW
authors.lastname: Basak
authors.forename: Kenneth W
authors.initials: KW
authors.lastname: Douglas
authors.forename: Ian H
authors.initials: IH
authors.lastname: Gabriel
authors.forename: Catarina
authors.initials: C
authors.lastname: Geraldes
authors.forename: Kai
authors.initials: K
authors.lastname: Hübel
authors.forename: Ozren
authors.initials: O
authors.lastname: Jaksic
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Koristek
authors.forename: Francesco
authors.initials: F
authors.lastname: Lanza
authors.forename: Roberto
authors.initials: R
authors.lastname: Lemoli
authors.forename: Gabor
authors.initials: G
authors.lastname: Mikala
authors.forename: Dominik
authors.initials: D
authors.lastname: Selleslag
authors.forename: Rafael F
authors.initials: RF
authors.lastname: Duarte
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001596:Benzylamines; D001781:Blood Component Removal / Q000379:methods*; D001859:Bone Neoplasms / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D000080027:Cyclams; D005060:Europe; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy; D009447:Neuroblastoma / Q000188:drug therapy; D012512:Sarcoma, Ewing / Q000188:drug therapy; D033581:Stem Cell Transplantation / Q000379:methods*; D014923:Wiskott-Aldrich Syndrome / Q000188:drug therapy; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor